JSDT. http://www.jsdt.or.jp/info/4032.html.online. Accessed 2021

Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42:681–3. https://doi.org/10.1093/eurheartj/ehaa1012.

Article  PubMed  PubMed Central  Google Scholar 

Heyse A, Manhaeghe L, Mahieu E, Vanfraechem C, Van Durme F. Sacubitril/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Fail. 2019;6:1331–3. https://doi.org/10.1002/ehf2.12544.

Article  PubMed  PubMed Central  Google Scholar 

Lee S, Oh J, Kim H, Ha J, Chun KH, Lee CJ, Park S, Lee SH, Kang SM. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail. 2020;7:1125–9. https://doi.org/10.1002/ehf2.12659.

Article  PubMed  PubMed Central  Google Scholar 

Feng Y, Li W, Liu H, Chen X. Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: a case report. Medicine (Baltimore). 2022;101: e29186. https://doi.org/10.1097/md.0000000000029186.

Article  CAS  PubMed  Google Scholar 

Lihua W, Cheng L, Chen H, Wei F, Jiang A. Use of angiotensin receptor neprilysin inhibitor in patients on maintenance hemodialysis with reduced cardiac ejection fraction, real-world experience from a single center. Iran J Kidney Dis. 2021;15:288–99. https://doi.org/10.52547/ijkd.5875.

Article  PubMed  Google Scholar 

Kong P, Dou Y, Wang X, Xiao J, Zhao Z. The effect of sacubitril/valsartan in a dialysis patient with severe heart failure. Case Rep Clin Med. 2021;10:197–202. https://doi.org/10.4236/crcm.2021.107025.

Article  Google Scholar 

Daimon S, Yasuda M, Maeda K. Effect of sacubitril/valsartan on cardiac function in hemodialysis patients. Ther Apher Dial. 2021;26:244–5. https://doi.org/10.1111/1744-9987.13715.

Article  PubMed  Google Scholar 

Iwashima Y, Fukushima H, Horio T, Rai T, Ishimitsu T. Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension. J Clin Hypertens (Greenwich). 2023;25:304–8. https://doi.org/10.1111/jch.14635.

Article  CAS  PubMed  Google Scholar 

Daimon S, Sakamoto Y, Yasuda M, Nishitani M. Long-term cardiac effect of sacubitril-valsartan in hemodialysis patients with a reduced ejection fraction after aortic valve replacement for aortic stenosis: a case report with literature review. Ren Replace Ther. 2023;9:19. https://doi.org/10.1186/s41100-023-00473-4.

Article  Google Scholar 

D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail. 2017;19:710–7. https://doi.org/10.1002/ejhf.799.

Article  CAS  PubMed  Google Scholar 

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077.

Article  CAS  PubMed  Google Scholar 

Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD. Association of change in N-Terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322:1085–95. https://doi.org/10.1001/jama.2019.12821.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murphy SP, Prescott MF, Camacho A, Iyer SR, Maisel AS, Felker GM, Butler J, Piña IL, Ibrahim NE, Abbas C, Burnett JC Jr, Solomon SD, Januzzi JL. Atrial natriuretic peptide and treatment with sacubitril/valsartan in heart failure with reduced ejection fraction. JACC Heart Fail. 2020;9:127–36. https://doi.org/10.1016/j.jchf.2020.09.013.

Article  PubMed  Google Scholar 

Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type peptide, high sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem. 2004;50:2279–85.

Article  CAS  PubMed  Google Scholar 

Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Michael FG, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco PM, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac society of Australia and New Zealand, and Chinese heart failure association. Eur J Heart Fail. 2021;23:352–80. https://doi.org/10.1002/ejhf.2115.

Article  PubMed  Google Scholar 

Naito T, Masaki T, Shimizu Y, Ogawa T, Ochiai M, Hamaguchi N, Hirashio S, Doi T, Yokoyama Y, Yorioka N. N-terminal pro brain natriuretic peptide predicts hospitalization of hemodialysis patients for cardiovascular disease. Nihon Jinzo Gakkai Shi. 2011;53:633–41.

CAS  PubMed  Google Scholar 

Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 2002;90:1284–9. https://doi.org/10.1016/s0002-9149(02)02864-3.

Article  PubMed  Google Scholar 

Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Arango JL, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141:352–61. https://doi.org/10.1161/circulationaha.119.044586.

Article  PubMed  Google Scholar 

Feng Z, Wang X, Zhang L, Apaer R, Xu L, Ma J, Li X, Che H, Tang B, Xiong Y, Xia Y, Xiao J, Su X, Wang Y, Dou X, Chen J, Mei L, Xue Z, Kong Y, Li S, Zhang H, Lin T, Wen F, Fu X, Tao Y, Fu L, Li Z, Huang R, Ye Z, He C, Shi W, Liang X, Ke G, Liu S. Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in maintenance hemodialysis patients with heart failure. Blood Purif. 2021;51:270–9. https://doi.org/10.1159/000519643.

Article  CAS  PubMed  Google Scholar 

Gan L, Lyu X, Yang X, Zhao Z, Tang Y, Chen Y, Yao Y, Hong F, Xu Z, Chen J, Gu L, Mao H, Liu Y, Sun J, Zhou Z, Du X, Jiang H, Li Y, Sun N, Liang X, Zuo L. Application of angiotensin receptor-neprilysin inhibitor in chronic kidney disease patients: Chinese expert consensus. Front Med (Lausanne). 2022;9: 877237.

Article  PubMed  Google Scholar